- Home
- RNXT vs XLO Comparison
RNXT vs XLO Comparison
Compare RNXT & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- XLO
- Stock Information
- Founded
- RNXT 2012
- XLO 2016
- Country
- RNXT United States
- XLO United States
- Employees
- RNXT N/A
- XLO N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- XLO Health Care
- Exchange
- RNXT Nasdaq
- XLO Nasdaq
- Market Cap
- RNXT 44.6M
- XLO 35.7M
- IPO Year
- RNXT 2021
- XLO 2021
- Fundamental
- Price
- RNXT $1.26
- XLO $0.76
- Analyst Decision
- RNXT Strong Buy
- XLO Buy
- Analyst Count
- RNXT 2
- XLO 2
- Target Price
- RNXT $7.50
- XLO $3.00
- AVG Volume (30 Days)
- RNXT 648.4K
- XLO 948.8K
- Earning Date
- RNXT 11-12-2025
- XLO 11-06-2025
- Dividend Yield
- RNXT N/A
- XLO N/A
- EPS Growth
- RNXT N/A
- XLO N/A
- EPS
- RNXT N/A
- XLO N/A
- Revenue
- RNXT $662,000.00
- XLO $15,001,000.00
- Revenue This Year
- RNXT $2,895.35
- XLO $519.70
- Revenue Next Year
- RNXT $313.04
- XLO $44.57
- P/E Ratio
- RNXT N/A
- XLO N/A
- Revenue Growth
- RNXT N/A
- XLO 536.45
- 52 Week Low
- RNXT $0.75
- XLO $0.62
- 52 Week High
- RNXT $1.69
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- RNXT 58.65
- XLO 62.46
- Support Level
- RNXT $1.19
- XLO $0.71
- Resistance Level
- RNXT $1.45
- XLO $0.78
- Average True Range (ATR)
- RNXT 0.12
- XLO 0.04
- MACD
- RNXT 0.02
- XLO 0.01
- Stochastic Oscillator
- RNXT 62.75
- XLO 71.63
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).